A Phase Ib Single-arm, Open-label, Multicenter Study to Assess the Safety and Tolerability of Combined Treatment With Nilotinib 300mg BID and Ruxolitinib Increasing Dose in CML and Ph+ ALL Patients
Phase of Trial: Phase I
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs Nilotinib (Primary) ; Ruxolitinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms CoRNea
- Sponsors Novartis Pharmaceuticals
- 30 Sep 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 11 May 2018 Planned End Date changed from 8 Aug 2019 to 19 Aug 2019.